Peroxisome_NN
proliferator-activated_JJ
receptor_NN
activators_NNS
target_VBP
human_JJ
endothelial_JJ
cells_NNS
to_TO
inhibit_VB
leukocyte-endothelial_JJ
cell_NN
interaction_NN
._.

An_DT
early_JJ
event_NN
in_IN
acute_JJ
and_CC
chronic_JJ
inflammation_NN
and_CC
associated_JJ
diseases_NNS
such_JJ
as_IN
atherosclerosis_NN
and_CC
rheumatoid_JJ
arthritis_NN
is_VBZ
the_DT
induced_VBN
expression_NN
of_IN
specific_JJ
adhesion_NN
molecules_NNS
on_IN
the_DT
surface_NN
of_IN
endothelial_JJ
cells_NNS
-LRB-_-LRB-
ECs_NNS
-RRB-_-RRB-
,_,
which_WDT
subsequently_RB
bind_VB
leukocytes_NNS
._.

Peroxisome_NN
proliferator-activated_JJ
receptors_NNS
-LRB-_-LRB-
PPARs_NNS
-RRB-_-RRB-
,_,
members_NNS
of_IN
the_DT
nuclear_JJ
receptor_NN
superfamily_NN
of_IN
transcription_NN
factors_NNS
,_,
are_VBP
activated_VBN
by_IN
fatty_JJ
acid_NN
metabolites_NNS
,_,
peroxisome_NN
proliferators_NNS
,_,
and_CC
thiazolidinediones_NNS
and_CC
are_VBP
now_RB
recognized_VBN
as_IN
important_JJ
mediators_NNS
in_IN
the_DT
inflammatory_JJ
response_NN
._.

Whether_IN
PPAR_NN
activators_NNS
influence_VBP
the_DT
inflammatory_JJ
responses_NNS
of_IN
ECs_NNS
is_VBZ
unknown_JJ
._.

We_PRP
show_VBP
that_IN
the_DT
PPAR_NN
activators_NNS
15-deoxy-Delta_NN
-LRB-_-LRB-
12_CD
,_,
14_CD
-RRB-_-RRB-
-_CC
prostaglandin_NN
J_NN
-LRB-_-LRB-
2_CD
-RRB-_-RRB-
-LRB-_-LRB-
15d-PGJ_NN
-LRB-_-LRB-
2_CD
-RRB-_-RRB-
-RRB-_-RRB-
,_,
Wyeth_NN
14643_CD
,_,
ciglitazone_NN
,_,
and_CC
troglitazone_NN
,_,
but_CC
not_RB
BRL_NN
49653_CD
,_,
partially_RB
inhibit_VBP
the_DT
induced_VBN
expression_NN
of_IN
vascular_JJ
cell_NN
adhesion_NN
molecule-1_NN
-LRB-_-LRB-
VCAM-1_NN
-RRB-_-RRB-
,_,
as_IN
measured_VBN
by_IN
ELISA_NN
,_,
and_CC
monocyte_NN
binding_NN
to_TO
human_JJ
aortic_JJ
endothelial_JJ
cells_NNS
-LRB-_-LRB-
HAECs_NNS
-RRB-_-RRB-
activated_VBD
by_IN
phorbol_NN
12-myristate_NN
13-acetate_NN
-LRB-_-LRB-
PMA_NN
-RRB-_-RRB-
or_CC
lipopolysaccharide_NN
._.

The_DT
``_JJ
natural_JJ
''_NN
PPAR_NN
activator_NN
15d-PGJ_NN
-LRB-_-LRB-
2_CD
-RRB-_-RRB-
had_VBD
the_DT
greatest_JJS
potency_NN
and_CC
was_VBD
the_DT
only_RB
tested_VBN
molecule_NN
capable_JJ
of_IN
partially_RB
inhibiting_VBG
the_DT
induced_JJ
expression_NN
of_IN
E-selectin_NN
and_CC
neutrophil-like_JJ
HL60_NN
cell_NN
binding_NN
to_TO
PMA-activated_JJ
HAECs_NNS
._.

Intracellular_JJ
adhesion_NN
molecule-1_NN
induction_NN
by_IN
PMA_NN
was_VBD
unaffected_JJ
by_IN
any_DT
of_IN
the_DT
molecules_NNS
tested_VBN
._.

Both_CC
PPAR-alpha_NN
and_CC
PPAR-gamma_NN
mRNAs_NNS
were_VBD
detected_VBN
in_IN
HAECs_NNS
by_IN
using_VBG
reverse_JJ
transcription-polymerase_NN
chain_NN
reaction_NN
and_CC
a_DT
ribonuclease_NN
protection_NN
assay_NN
;_:
however_RB
,_,
we_PRP
have_VBP
yet_RB
to_TO
determine_VB
which_WDT
,_,
if_IN
any_DT
,_,
of_IN
the_DT
PPARs_NNS
are_VBP
mediating_VBG
this_DT
process_NN
._.

These_DT
results_NNS
suggest_VBP
that_IN
certain_JJ
PPAR_NN
activators_NNS
may_MD
help_VB
limit_NN
chronic_JJ
inflammation_NN
mediated_VBN
by_IN
VCAM-1_NN
and_CC
monocytes_NNS
without_IN
affecting_VBG
acute_JJ
inflammation_NN
mediated_VBN
by_IN
E-selectin_NN
and_CC
neutrophil_NN
binding_NN
._.

